| 1 |
NCT03389711 |
Recruiting |
INCMNSZ - Rheumatoid Arthritis Cohort |
- Early Rheumatoid Arthritis
- Rheumatoid Arthritis
|
- Combination Product: DMARD´s and multidisciplinary treatment
|
Observational |
|
- National Institute of Medical Sciences and Nutrition, Salvador Zubiran
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Disease activity status
- Change from Baseline of the Patient Reported Outcome : HAQ (Health Assessment Questionnarie)
- Change from Baseline of the Patient Reported Outcome: RADAI (Rheumatoid Arthritis Disease Activity Index)
- (and 5 more...)
|
210 |
All |
18 Years and older (Adult, Senior) |
NCT03389711 |
IRE-274-10/11-1 |
IRAC |
February 4, 2004 |
February 4, 2019 |
February 4, 2024 |
January 4, 2018 |
January 11, 2018 |
|
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, Tlalpan, Mexico
|
| 2 |
NCT02468986 |
Unknown † |
Study of Venous Endothelial Cells in Rheumatoid Arthritis |
|
|
Observational |
|
- University of Texas Southwestern Medical Center
- American Heart Association
- Bristol-Myers Squibb
|
Other / Industry |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Endothelial cell protein expression by immunofluorescence microscopy of endothelial nitric oxide synthase, nitrotyrosine, nuclear factor kappa B.
- Serum cytokines analysis by cytometric bead array
- Flow mediated dilation assessed in the brachial artery by ultrasound
|
45 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02468986 |
STU 012011034 |
|
November 2011 |
August 2015 |
December 2015 |
June 11, 2015 |
June 11, 2015 |
|
- Parkland Memorial Hospital
Dallas, Texas, United States - University of Texas Southwestern
Dallas, Texas, United States
|
| 3 |
NCT02051114 |
Recruiting |
Discovering the Antecedents of Rheumatoid Arthritis Flare |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- RNA transcripts that correlate with rheumatoid arthritis disease activity
|
25 |
Female |
40 Years to 65 Years (Adult) |
NCT02051114 |
DOR-0833 |
|
February 2014 |
February 2020 |
February 2020 |
January 31, 2014 |
October 20, 2017 |
|
- The Rockefeller University Hospital
New York, New York, United States
|
| 4 |
NCT01111357 |
Completed |
Study of Human Leukocyte Antigen (HLA) Polymorphisms in Patients With Rheumatoid Arthritis |
|
- Biological: Collect of 10 ml of peripheric blood for DNA extraction
|
Observational |
|
- University Hospital Center of Martinique
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Difference of distribution of HLA alleles in patients and in healthy controls
- The association between the different HLA alleles among French West-Indian RA patients and the autoantibodies production.
- The association between the different HLA alleles among French West-Indian RA patients and the radiological damage.
- The association between the different HLA alleles among French West-Indian RA patients and the response to therapy
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT01111357 |
09/B/02 |
HLAPRPA |
February 2010 |
August 2010 |
August 2010 |
April 27, 2010 |
December 21, 2010 |
|
- Service de rhumatologie CHU de Fort-de-France
Fort-de-France, Martinique
|
| 5 |
NCT02905175 |
Recruiting |
Rheumatoid Arthritis Patients and Porphyromonas Gingivalis |
|
- Procedure: blood sample
- Procedure: synovial tissue
|
Observational |
|
- Centre Hospitalier Universitaire de Saint Etienne
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Comparison of genetic signature after induction by P. gingivalis and P. intermedia on synoviocytes
- Comparison of specific transcriptome profile induced by P. gingivalis compared to P. intermedia on peripheral blood mononuclear cells (PBMC) and gingival fibroblasts
- Comparison of transcriptome profile between P. gingivalis and P. intermedia on RA synovial cells.
- Comparison of the transcriptomic profile between RA and osteoarthritis synoviocytes
|
5 |
All |
18 Years and older (Adult, Senior) |
NCT02905175 |
1408022 |
|
January 2015 |
October 2017 |
January 2018 |
September 19, 2016 |
January 13, 2017 |
|
- CHU Saint-Etienne
Saint-Etienne, France
|
| 6 |
NCT00504595 |
Completed
Has Results |
Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis |
|
- Drug: ACZ885 (investigational)
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Response to Treatment (ACR20) in Adult Patients With Established Rheumatoid Arthritis (RA)
- Efficacy of ACZ885 by Assessing the Response to Treatment Using the Simple Disease Index (SDAI)
- Efficacy of ACZ885 (Canakinumab) by Assessing the Response to Treatment Using the Disease Activity Score (DAS28)
|
80 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00504595 |
CACZ885A2207 |
|
May 2007 |
September 2008 |
September 2008 |
July 20, 2007 |
August 7, 2012 |
June 23, 2011 |
- Novartis Investigative site
Moscow, Russian Federation - Novartis investigative site
Barcelona, Spain - Novartis Investigative site
Bern, Switzerland - Novartis investigative site
Istanbul, Turkey
|
| 7 |
NCT02721004 |
Completed |
Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis |
|
|
Observational |
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- Disease Activity Score Based on 28-joints Count (DAS28)
- Simplified Disease Activity Index (SDAI) Score
- Clinical Disease Activity Index (CDAI) Score
- (and 4 more...)
|
592 |
All |
Child, Adult, Senior |
NCT02721004 |
ML22551 |
|
March 2009 |
December 2014 |
December 2014 |
March 28, 2016 |
July 4, 2016 |
|
|
| 8 |
NCT01783730 |
Completed
Has Results |
Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of Participants With Adverse Events
- Mean Disease Activity Score 28 (DAS28-4(ESR)) at Baseline
- Mean Disease Activity Score 28 (DAS28-4(ESR)) at Week 4
- (and 13 more...)
|
163 |
All |
15 Years to 99 Years (Child, Adult, Senior) |
NCT01783730 |
P13-983 |
|
February 2013 |
September 2015 |
September 2015 |
February 5, 2013 |
October 26, 2016 |
October 26, 2016 |
|
| 9 |
NCT02389283 |
Recruiting |
Reduced Ultrasound Counts in Rheumatoid Arthritis |
|
|
Observational |
|
- Hospital General Universitario Gregorio Marañon
- Roche Pharma AG
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Mode B and power Doppler (PD) ultrasound evaluation
- Dopler Ultrasound sensitivity to change comparison
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT02389283 |
FIBHGM-EONC004-2014 |
|
March 2015 |
April 2017 |
June 2017 |
March 17, 2015 |
April 18, 2017 |
|
- Hopsital general Universitario Gregorio Marañón
Madrid, Spain
|
| 10 |
NCT03336684 |
Active, not recruiting |
Evaluation of Rheumatoid Arthritis Disease Education Literature |
|
- Behavioral: Patient education
|
Interventional |
Not Applicable |
- University of Science Malaysia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Health Services Research
|
- Patient knowledge about rheumatoid arthritis
- Patient satisfaction
|
320 |
All |
18 Years and older (Adult, Senior) |
NCT03336684 |
PACT2 |
ERADEL |
December 18, 2017 |
May 31, 2018 |
June 30, 2018 |
November 8, 2017 |
February 20, 2018 |
|
- Clifton Central Hospital
Karachi, Sindh, Pakistan - Liaqat National Hospital
Karachi, Sindh, Pakistan
|
| 11 |
NCT01547091 |
Unknown † |
Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis |
|
- Biological: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)
- Drug: Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)
- Biological: UC-MSC+DMARDS
|
Interventional |
Phase 1
Phase 2 |
- Alliancells Bioscience Corporation Limited
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of MSC treatment.
- RA Serology
- Disease Activity Score (DAS 28) Index Mean Change From Baseline
- Patient's assessment of pain.
|
200 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01547091 |
Alliancells-1 |
RA |
April 2013 |
October 2014 |
December 2014 |
March 7, 2012 |
June 27, 2013 |
|
- The 323 Hospital of Chinese People's Liberation Army
Xi'an, Shaanxi, China
|
| 12 |
NCT01163318 |
Completed
Has Results |
Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Arthritis |
|
|
Observational |
|
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of Adverse Drug Reactions (ADRs)
- Incidence of Infections and Malignant Tumors
- Percentage of Participants With Disease Activity Score 28 - 4 Erythrocyte Sedimentation Rate (DAS28-4ESR) < 2.6 by Visit
- Percentage of Participants With Modified Health Assessment Questionnaire (MHAQ) Score ≤ 0.5 by Visit
|
552 |
All |
15 Years and older (Child, Adult, Senior) |
NCT01163318 |
P12-070 |
|
December 2009 |
May 2014 |
May 2014 |
July 15, 2010 |
June 10, 2015 |
June 10, 2015 |
|
| 13 |
NCT03445871 |
Not yet recruiting |
Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate |
|
- Biological: Blood sample
- Diagnostic Test: CRQ
|
Interventional |
Phase 4 |
- Centre Hospitalier Universitaire de Saint Etienne
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTX-PG concentration
- different metabolites dosing of MTX-PG
- CQR score
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT03445871 |
1708155
2017-004348-39 |
POLYGLU |
March 2018 |
January 2020 |
January 2020 |
February 26, 2018 |
March 14, 2018 |
|
- Chu Saint Etienne
Saint-etienne, France
|
| 14 |
NCT02960958 |
Enrolling by invitation |
Metabolome Analysis in Patients With Rheumatoid Arthritis |
|
|
Observational |
|
- The Catholic University of Korea
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Metabolic fingerprint of rheumatoid arthritis
- Correlations between specific metabolites and disease activity/severity of RA
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02960958 |
CiRAD1 |
|
November 20, 2016 |
October 2018 |
October 2019 |
November 10, 2016 |
January 25, 2018 |
|
|
| 15 |
NCT01144598 |
Completed
Has Results |
Time to DMARD (Disease-Modifying Anti-Rheumatic Drug) Treatment and Actual Work Limitation of Patients With Rheumatoid Arthritis in Turkey |
|
|
Observational |
|
|
Industry |
- Time Perspective: Cross-Sectional
|
- Evaluation of Disease Duration: Time From Diagnosis to Disease-Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis
- Work Limitation: Health Assessment Questionnaire-Disability Index (HAQ-DI)
- Work Limitation: Work Productivity and Activity Impairment (WPAI) Questionnaire
- (and 12 more...)
|
356 |
All |
18 Years and older (Adult, Senior) |
NCT01144598 |
P12-087 |
|
February 2010 |
August 2011 |
August 2011 |
June 15, 2010 |
October 2, 2012 |
September 19, 2012 |
- Site Reference ID/Investigator# 39111
Adana, Turkey - Site Reference ID/Investigator# 39102
Ankara, Turkey - Site Reference ID/Investigator# 39104
Ankara, Turkey - (and 18 more...)
|
| 16 |
NCT02089087 |
Completed |
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients |
|
- Biological: CFZ533
- Drug: Placebo
|
Interventional |
Phase 1 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of patients with adverse events as a measure of safety and tolerability
- Plasma Pharmacokinetics (PK) of CFZ533: Area Under the Plasma Concentration-time Curve (AUC)
- Plasma Pharmacokinetics (PK) of CFZ533: Observed Maximum Plasma Concentration Following Drug Administration (Cmax)
- (and 3 more...)
|
75 |
All |
18 Years to 55 Years (Adult) |
NCT02089087 |
CCFZ533X2101 |
|
January 7, 2013 |
February 3, 2017 |
February 3, 2017 |
March 17, 2014 |
August 7, 2017 |
|
- Novartis Investigative Site
Anniston, Alabama, United States - Novartis Investigative Site
Miami, Florida, United States - Novartis Investigative Site
South Miami, Florida, United States - (and 3 more...)
|
| 17 |
NCT02643823 |
Unknown † |
Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis |
|
- Biological: hUC-MSC + DMARDs
- Drug: DMARDs
|
Interventional |
Phase 1 |
- Shenzhen Hornetcorn Bio-technology Company, LTD
- Futian People's Hospital
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Severity of adverse events
- RA Serology
- Disease Activity Score (DAS 28) Index
|
40 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02643823 |
HYK-Rheumatoid Arthritis |
|
January 2016 |
January 2017 |
June 2017 |
December 31, 2015 |
May 24, 2016 |
|
- The Fourth People's Hospital of Shenzhen
Shenzhen, Guangdong, China
|
| 18 |
NCT01228812 |
Completed |
Physical Activity Behavior of Rheumatoid Arthritis Patients and Healthy Controls |
|
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Physical activity
- Functional status
- Pain
- (and 2 more...)
|
|
All |
40 Years to 80 Years (Adult, Senior) |
NCT01228812 |
PR_AP |
|
April 2010 |
September 2010 |
September 2010 |
October 27, 2010 |
October 27, 2010 |
|
- Centre Hospitalier Universitaire Vaudois, Département de l'Appareil Locomoteur
Lausanne, Switzerland
|
| 19 |
NCT01782469 |
Terminated
Has Results |
Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population |
|
|
Observational |
|
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Mean Change in Synovitis Measured by B-modal Ultrasonography Assessment Score After 13 Weeks of Treatment With Adalimumab.
- Mean Percent Reduction in Ultrasonography Assessment Score
- Mean Number of Joints With Detected Erosions
- (and 2 more...)
|
16 |
All |
18 Years and older (Adult, Senior) |
NCT01782469 |
P13-708 |
|
October 2012 |
July 2014 |
July 2014 |
February 4, 2013 |
July 30, 2015 |
July 30, 2015 |
|
| 20 |
NCT02157012 |
Recruiting |
Evaluation of the Condition of Rheumatoid Arthritis After Treatment |
|
- Drug: The effectiveness of Xeljanz in rheumatoid arthritis patients
|
Interventional |
Phase 4 |
- Shinshu University
- Showa Inan General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline of clinical evaluation in rheumatoid arthritis
- Number of participants with adverse events
|
100 |
All |
20 Years to 90 Years (Adult, Senior) |
NCT02157012 |
Xeljanz2014 |
|
May 2014 |
April 2016 |
March 2019 |
June 5, 2014 |
October 13, 2017 |
|
- Yukio Nakamura
Matsumoto, Nagano, Japan
|
| 21 |
NCT02675803 |
Completed |
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients |
|
- Biological: VAY736
- Biological: VAY736 placebo
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Safety and tolerability as measured by the number of patients wth adverse events
- Absolute bioavailability of VAY736: The ratio of area under curve (AUC) for s.c dose and for intravenous dose
- Plasma pharmacokinetics of VAY736: The area under the plasma concentration-time curve from time zero to the end of the dosing interval (AUCtau)
- (and 11 more...)
|
65 |
All |
18 Years to 65 Years (Adult) |
NCT02675803 |
CVAY736X2101
2010-020156-65 |
|
December 20, 2010 |
January 22, 2018 |
January 22, 2018 |
February 5, 2016 |
February 12, 2018 |
|
- Novartis Investigative Site
Berlin, Germany
|
| 22 |
NCT01388608 |
Completed |
Standard Disease Activity Parameters and Step Activity in Patients With Rheumatoid Arthritis Receiving Etanercept |
|
|
Observational |
|
- University Hospital Muenster
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Changes from baseline in the step counts during a therapy with etanercept in patients with active rheumatoid arthritis
- Correlation of the step counts with the health-assessment-questionnaire and the disease activity measured by DAS28 during a therapy with etanercept
|
28 |
All |
18 Years to 76 Years (Adult, Senior) |
NCT01388608 |
StepcountETN |
|
June 2009 |
January 2013 |
April 2013 |
July 6, 2011 |
August 21, 2013 |
|
- University Hospital Muenster
Muenster, Germany
|
| 23 |
NCT02368093 |
Completed
Has Results |
Efficacy Study of Dextromethorphan to Treat Rheumatoid Arthritis |
|
- Drug: Dextromethorphan hydrobromide
|
Interventional |
Not Applicable |
- Taichung Veterans General Hospital
- TSH Biopharm Corporation Limited
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Good European League Against Rheumatism (EULAR) Therapeutic Response Rate
|
48 |
All |
18 Years and older (Adult, Senior) |
NCT02368093 |
C09060-1 |
|
January 2010 |
September 2012 |
September 2012 |
February 20, 2015 |
March 31, 2015 |
March 31, 2015 |
|
| 24 |
NCT00244556 |
Completed |
Study Comparing Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Active Rheumatoid Arthritis Despite Current Methotrexate Therapy |
|
- Drug: Methotrexate plus ENBREL or ENBREL alone
|
Interventional |
Phase 4 |
- Wyeth is now a wholly owned subsidiary of Pfizer
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To assess the efficacy and safety of substituting ENBREL versus adding ENBREL to Methotrexate in patients with active Rheumatoid Arthritis despite adequate Methotrexate therapy.
- To evaluate the effect of combination therapy with ENBREL plus Methotrexate versus ENBREL alone on health-related quality of life measures.
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT00244556 |
0881A-101136 |
|
March 2003 |
May 2004 |
May 2004 |
October 26, 2005 |
February 21, 2013 |
|
|
| 25 |
NCT02627924 |
Completed |
Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab |
|
|
Observational |
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Change from baseline in Health Assessment Questionnaire Disability Index (HAQ DI) score at week 24
- Percentage of subjects achieving a clinically meaningful improvement on the HAQ DI from baseline
- Healthcare Resource Utilization (HCRU)
- (and 4 more...)
|
89 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02627924 |
P15-777 |
ROCKA |
November 18, 2015 |
December 28, 2017 |
December 28, 2017 |
December 11, 2015 |
January 25, 2018 |
|
- Eulji University Hospital
Daejeon, Korea, Republic of - Hanyang University Guri Hosp
Guri-si, Korea, Republic of - The Catholic Univ. of Korea
Gyeonggi-do, Korea, Republic of - (and 7 more...)
|
| 26 |
NCT03333681 |
Active, not recruiting |
Evaluation of Stem Cell Therapy Effects on the Immune Response in Rheumatoid Arthritis Patients |
|
- Biological: Autologous mesenchymal stem cells
|
Interventional |
Phase 1 |
- Mashhad University of Medical Sciences
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Effect of mesenchymal stem cells therapy on the percentage of regulatory T cells
|
15 |
Female |
35 Years to 60 Years (Adult) |
NCT03333681 |
931523
122 |
|
June 20, 2016 |
September 20, 2018 |
December 20, 2018 |
November 7, 2017 |
November 7, 2017 |
|
|
| 27 |
NCT02078375 |
Suspended |
The PRESS RA: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis |
|
- Dietary Supplement: Protein
- Dietary Supplement: Carbohydrate (Placebo)
- Other: Resistance Exercise Program
|
Interventional |
Not Applicable |
- Johns Hopkins University
- National Institute on Aging (NIA)
- American College of Rheumatology Research and Education Foundation
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Other
|
- Body composition
- Muscle strength
|
50 |
All |
60 Years to 95 Years (Adult, Senior) |
NCT02078375 |
115687
R03AG045081 |
PRESSRA |
February 2014 |
June 30, 2018 |
June 30, 2018 |
March 5, 2014 |
March 29, 2018 |
|
- Johns Hopkins Bayview Campus
Baltimore, Maryland, United States
|
| 28 |
NCT00781989 |
Completed |
Ultrasonography as a Biomarker in Early Rheumatoid Arthritis |
|
|
Observational |
|
- Imperial College London
- Medical Research Council
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Correlation between Power Doppler Ultrasound (PDUS)score at baseline and progression of erosions at one year, as assessed by xray and high frequency ultrasound.
- Correlation between average Power Doppler Ultrasound (PDUS) score (at 0,6 and 12 months) and progression of erosions at one year,as assessed by xray and high frequency ultrasound.
- Correlation between CRP level at baseline and progression of erosions at one year,as assessed by xray and high frequency ultrasound.
|
101 |
All |
18 Years and older (Adult, Senior) |
NCT00781989 |
CRO1089
Sponsers number: TAYP2013
Funder's number: G0601962 |
|
September 2008 |
April 2011 |
April 2011 |
October 29, 2008 |
September 30, 2011 |
|
- Kennedy Institute Clinical Trials Unit, 4 West, Charing Cross Hospital
London, United Kingdom
|
| 29 |
NCT01752855 |
Completed
Has Results |
Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab |
|
- Biological: New formulation adalimumab
|
Interventional |
Phase 2 |
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Weeks 36 and 48
- Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Weeks 36 and 48
- Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Weeks 36 and 48
- (and 2 more...)
|
88 |
All |
18 Years and older (Adult, Senior) |
NCT01752855 |
M13-692
2012-003881-42 |
|
December 2012 |
October 2013 |
October 2013 |
December 19, 2012 |
October 29, 2014 |
October 29, 2014 |
- Site Reference ID/Investigator# 92113
Mesa, Arizona, United States - Site Reference ID/Investigator# 92118
Hemet, California, United States - Site Reference ID/Investigator# 92117
Wichita, Kansas, United States - (and 17 more...)
|
| 30 |
NCT00074555 |
Completed |
Registry for African Americans With Early Rheumatoid Arthritis |
|
|
Observational |
|
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Radiographic severity of rheumatoid arthritis in African Americans
|
357 |
All |
18 Years and older (Adult, Senior) |
NCT00074555 |
N01 AR02247
NIAMS-106 |
CLEAR |
January 2001 |
December 2011 |
March 2012 |
December 17, 2003 |
January 6, 2016 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Emory University
Atlanta, Georgia, United States - Washington University at St. Louis
St. Louis, Missouri, United States - (and 2 more...)
|
| 31 |
NCT01078116 |
Completed
Has Results |
Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis (RA) |
|
|
Observational |
|
- Abbott
- Institute of Political Economical & Social Researches, Greece
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Estimation of the Direct and Indirect Cost Incurred by Adalimumab Treatment
- Health Related Quality of Life (European Quality of Life 5 Dimensions)
- Health Related Quality of Life (Health Assessment Questionnaire)
- (and 2 more...)
|
124 |
All |
18 Years and older (Adult, Senior) |
NCT01078116 |
P10-159 |
HEOR |
November 2007 |
June 2010 |
June 2010 |
March 2, 2010 |
August 11, 2011 |
July 25, 2011 |
- Site Reference ID/Investigator# 32052
Athens, Greece - Site Reference ID/Investigator# 32068
Athens, Greece - Site Reference ID/Investigator# 32069
Athens, Greece - (and 7 more...)
|
| 32 |
NCT02984943 |
Enrolling by invitation |
The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis |
|
- Device: Hyperbaric Oxygen
|
Interventional |
Not Applicable |
- David Grant U.S. Air Force Medical Center
|
U.S. Fed |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Ultrasound measurement of joint progression alteration
- MRI measurement of joint progression alteration
- Change in disease activity of Rheumatoid Arthritis assessed at baseline and six months
- (and 4 more...)
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT02984943 |
FDG20160004H |
|
November 2016 |
August 2018 |
November 2018 |
December 7, 2016 |
February 2, 2018 |
|
|
| 33 |
NCT00195338 |
Completed
Has Results |
Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Percentage of Participants With Completion of Study Treatment
- Change From Baseline in Number of Joints With Active Synovitis at Months 6, 12, 18, 30, 42, 54 and 66
- (and 2 more...)
|
25 |
All |
17 Years and older (Child, Adult, Senior) |
NCT00195338 |
0881-101343 |
|
May 2004 |
December 2010 |
December 2010 |
September 19, 2005 |
January 23, 2012 |
January 23, 2012 |
- Pfizer Investigational Site
Luxembourg, Luxembourg
|
| 34 |
NCT01736189 |
Active, not recruiting |
Special Investigation in Patients With Rheumatoid Arthritis (Combo Study; Adalimumab With High Dose Methotrexate) |
|
|
Observational |
|
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Disease activity Score 28
- Simplified disease activity index
- Health Assessment Questionnaire
- (and 3 more...)
|
354 |
All |
16 Years to 99 Years (Child, Adult, Senior) |
NCT01736189 |
P13-684 |
|
September 14, 2012 |
April 16, 2018 |
April 16, 2018 |
November 29, 2012 |
February 1, 2018 |
|
- Nagoya City University Hospital
Nagoya-shi, Aichi, Japan - Hyogo College of Medicine Hosp
Nishinomiya, Hyogo, Japan - Yokohama City Univ Medical Ctr
Yokohama, Kanagawa, Japan - (and 134 more...)
|
| 35 |
NCT01640054 |
Terminated
Has Results |
A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis |
|
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Patients Who Had at Least 1 Adverse Event in Any Category
- Components of ACR Response Criteria Over Time
- DAS28-CRP Score Over Time
- (and 2 more...)
|
115 |
All |
18 Years and older (Adult, Senior) |
NCT01640054 |
D4300C00029 |
OSKIRA-Asia-1X |
July 2012 |
July 2013 |
July 2013 |
July 13, 2012 |
March 28, 2014 |
January 9, 2014 |
- Research Site
Hongkong, Shatin, Hong Kong - Research Site
Hong Kong, Hong Kong - Research Site
Fukuoka-shi, Fukuoka, Japan - (and 23 more...)
|
| 36 |
NCT01202760 |
Completed |
A Rheumatoid Arthritis Study in Patients |
|
- Drug: LY2127399
- Drug: Placebo every 4 weeks
- Drug: Placebo every 2 weeks
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percentage of patients with American College of Rheumatology 20% response (ACR20)
- Percentage of patients with American College of Rheumatology 50% (ACR50) and 70% (ACR70) response
- Mean percent improvement in ACR-N
- (and 15 more...)
|
1002 |
All |
18 Years and older (Adult, Senior) |
NCT01202760 |
12978
H9B-MC-BCDO
CTRI/2011/07/001867 |
FLEX O |
January 2011 |
December 2012 |
July 2013 |
September 16, 2010 |
August 27, 2013 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Birmingham, Alabama, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Paradise Valley, Arizona, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Peoria, Arizona, United States - (and 210 more...)
|
| 37 |
NCT01616641 |
Completed |
Orofacial Evaluation in Women With Rheumatoid Arthritis |
|
|
Observational |
|
- Federal University of São Paulo
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
|
150 |
Female |
18 Years to 65 Years (Adult) |
NCT01616641 |
Orofacial |
|
June 2011 |
|
June 2012 |
June 12, 2012 |
June 12, 2012 |
|
|
| 38 |
NCT00947492 |
Unknown † |
Monitoring Epstein-Barr Virus (EBV) Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs |
|
- Biological: Venous blood sample
|
Interventional |
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- to monitor Epstein Barr Virus load over time in patients with Rheumatoid arthritis under Orencia* (abatacept) or RoActemra* (tocilizumab)
- to detect possible immunosuppression associated EBV dysregulation, as seen in post transplant lymphoproliferative disease
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT00947492 |
2009-07
2009-A00247-50 |
|
June 2009 |
September 2014 |
December 2014 |
July 28, 2009 |
August 28, 2014 |
|
- Assistance Publique-Hopitaux de Marseille
Marseille, France
|
| 39 |
NCT02414984 |
Terminated |
Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Treatment Adherence Measured by Continuous Measures of Medication Gaps (CMG)
- Frequency of Treatment Suspension
- Number of Treatment Termination
- (and 9 more...)
|
37 |
All |
18 Years and older (Adult, Senior) |
NCT02414984 |
CR105492
CNTO148ARA4004 |
Go-Compl-Ar |
March 2015 |
November 2016 |
November 2016 |
April 13, 2015 |
February 13, 2017 |
|
- Barranquilla, Colombia
- Bogota, Colombia
- Bogotá, Colombia
- (and 4 more...)
|
| 40 |
NCT02541955 |
Recruiting |
Use of Acthar in Rheumatoid Arthritis (RA) Related Flares |
- Rheumatoid Arthritis (RA)
|
|
Interventional |
Phase 4 |
- Dr. Veena Ranganath
- University of California, Los Angeles
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Ultrasound Power Doppler Score
- DAS28
- Ultrasound Grey Scale Synovial Hypertrophy score
- HAQ-DI
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02541955 |
Acthar in Rheumatoid Arthritis |
|
July 20, 2017 |
June 2019 |
December 2019 |
September 4, 2015 |
October 26, 2017 |
|
- UCLA David Geffen School of Medicine, Division of Rheumatology
Los Angeles, California, United States
|
| 41 |
NCT01414101 |
Completed |
Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis |
|
- Drug: ISIS CRP Rx or Placebo
|
Interventional |
Phase 2 |
- Ionis Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
51 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01414101 |
ISIS 329993-CS3 |
|
August 2011 |
May 2013 |
May 2013 |
August 11, 2011 |
May 17, 2013 |
|
- Isis Investigational site
Kamloops, British Columbia, Canada - Isis Investigational Site
Toronto, Ontario, Canada - Isis Investigational Site
Montreal, Quebec, Canada - (and 7 more...)
|
| 42 |
NCT01600521 |
Completed |
A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications |
|
- Drug: A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs
|
Interventional |
Not Applicable |
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The relief of rheumatoid arthritis symptoms and the improvement of functions assessed by the American College of Rheumatology (ACR) core set measures.
- The adverse effects associated with the treatments
|
1748 |
All |
18 Years and older (Adult, Senior) |
NCT01600521 |
1205E14290 |
|
November 2004 |
April 2011 |
March 2012 |
May 17, 2012 |
April 8, 2015 |
|
- Beijing Friendship Hospital, Affiliated to Capital Medical University
Beijing, China - Institute of Chinese Medical Sciences, University of Macau
Taipa, China
|
| 43 |
NCT00948610 |
Completed
Has Results |
Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy |
|
|
Interventional |
Not Applicable |
- University of California, Los Angeles
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Slow Wave Sleep
- Cellular Inflammation
|
20 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT00948610 |
NHLBI RO1 HL079955 |
|
November 2008 |
April 2011 |
April 2011 |
July 29, 2009 |
December 2, 2017 |
September 12, 2017 |
- University of California, Los Angeles, General Clinical Research Center
Los Angeles, California, United States
|
| 44 |
NCT01948388 |
Active, not recruiting |
The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients |
|
- Drug: corticotrophin 80 units
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Disease Activity Index (CDAI) score Evaluation
- Evaluation of MRI structural improvements
- Change from baseline in erosions as measured by Magnetic Resonance Imaging (MRI)
- (and 5 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT01948388 |
RA2013-01 |
|
September 2013 |
September 2016 |
September 2016 |
September 23, 2013 |
August 10, 2016 |
|
- AARDS Research, Inc
Aventura, Florida, United States
|
| 45 |
NCT01215942 |
Completed |
An Open Label Study for Patients With Rheumatoid Arthritis |
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of patients developing anti-LY2127399 antibodies
- Change from baseline in absolute B cell counts
- Change from baseline in serum immunoglobulin (Ig) levels
- (and 12 more...)
|
1505 |
All |
18 Years and older (Adult, Senior) |
NCT01215942 |
13419
H9B-MC-BCDP |
|
June 2011 |
February 2014 |
February 2014 |
October 7, 2010 |
May 6, 2014 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Birmingham, Alabama, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Huntsville, Alabama, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Peoria, Arizona, United States - (and 324 more...)
|
| 46 |
NCT00439062 |
Completed |
Treatment of Rheumatoid Arthritis With Roxithromycin |
|
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The primary efficacy variable was the percentage of patients who had a 20 percent improvement according to American College of Rheumatology (ACR) criteria (an ACR 20 response) at six months.
- Secondary outcome measures were 50 percent improvement and 70 percent improvement according to ACR criteria (an ACR 50 response and an ACR 70 response, respectively).
|
100 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00439062 |
RA-89861966 |
|
June 2006 |
|
June 2006 |
February 22, 2007 |
February 22, 2007 |
|
- Nazilli State Hospital
Nazilli, Aydin, Turkey
|
| 47 |
NCT01198002 |
Completed |
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate |
|
- Drug: LY2127399
- Drug: Placebo every 2 weeks
- Drug: Placebo every 4 weeks
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of patients with American College of Rheumatology 20% response (ACR20) at Week 24
- Change from baseline to Week 52 in van der Heijde modified Total Sharp Score (mTSS)
- Change from baseline to Week 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI)
- (and 27 more...)
|
990 |
All |
18 Years and older (Adult, Senior) |
NCT01198002 |
11352
H9B-MC-BCDM
CTRI/2011/07/001870 |
FLEX M |
December 2010 |
December 2012 |
January 2014 |
September 9, 2010 |
April 29, 2014 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Birmingham, Alabama, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Huntsville, Alabama, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Paradise Valley, Arizona, United States - (and 231 more...)
|
| 48 |
NCT01408602 |
Unknown † |
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients |
|
- Drug: MRC375
- Drug: Matching Placebo
- Drug: MRC375 150mg
|
Interventional |
Phase 2 |
- Molecular Research Center, Inc.
- Camargo Pharmaceutical Services
- Clin Data Services
- (and 3 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Efficacy evaluated of both doses of MRC375 compared to placebo after 24 weeks of treatment as measured by the rate of achievement of 20% improvement in ACR criteria
- Safety and tolerability of both doses of MRC375
- Compare the Efficacy of two doses of MRC375 when compared to a placebo for the change from baseline screening in each of the individual ACR components measuring RA after 24 weeks of treatment
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT01408602 |
MRC2011-001 |
|
November 2011 |
July 2014 |
July 2014 |
August 3, 2011 |
May 12, 2014 |
|
- Mobile Diagnostic Center Rheumatology
Mobile, Alabama, United States - Valerius Medical Group
Long Beach, California, United States - Trial Concierge/Pacific Clinical Studies
Los Alamitos, California, United States - (and 16 more...)
|
| 49 |
NCT01202773 |
Completed |
A Study in Patients With Rheumatoid Arthritis |
|
- Drug: LY2127399
- Drug: Placebo every 4 weeks
- Drug: Placebo every 2 weeks
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percentage of patients with American College of Rheumatology 20% response (ACR20)
- Percentage of patients with American College of Rheumatology 50% (ACR50) and 70% (ACR70) response
- Mean percent improvement in ACR-N
- (and 18 more...)
|
555 |
All |
18 Years and older (Adult, Senior) |
NCT01202773 |
13732
H9B-MC-BCDV |
FLEX V |
January 2011 |
March 2013 |
January 2014 |
September 16, 2010 |
May 7, 2014 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Birmingham, Alabama, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Huntsville, Alabama, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Paradise Valley, Arizona, United States - (and 198 more...)
|
| 50 |
NCT02030028 |
Recruiting |
ACTH Gel Therapy in Rheumatoid Arthritis |
|
|
Interventional |
Not Applicable |
- Dr. Larry W. Moreland
- Mallinckrodt
- University of Pittsburgh
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in Clinical Disease Activity Index
- Change in the Disease Activity Score
- Changes in acute phase reactants
- Patient reported changes in fatigue
|
20 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02030028 |
PRO13080577 |
|
November 2014 |
August 2018 |
October 2018 |
January 8, 2014 |
September 12, 2017 |
|
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
|
Create an RSS feed from your search for:
Download the search results for: